Skip to content

Type 1 diabetes — patient experience and advocacy

TL;DR — T1D is lived as continuous risk management: insulin access, glucose decisions, food, activity, sleep, devices, disclosure, and contingency planning. Published syntheses document parental vigilance, fear of hypoglycemia, stigma, diabetes distress, and the unequal distribution of technology (Whittemore 2012, PMID 22581804; Zhang 2020, PMID 33091198; Embick 2024, PMID 38361327; Agarwal 2021, PMID 33155826). Advocacy has shifted language, funded research, pressured insulin-access systems, and promoted screening and technology, but organization priorities are not interchangeable with representative patient-preference data. Ethical synthesis requires public sources, aggregate themes, and explicit coverage limits.

Daily workload

Task domain Recurring work Failure consequence
Insulin Dose, time, carry, store, replenish Hypoglycemia or ketosis/DKA
Glucose Interpret current value and trend Delayed or excessive correction
Food Estimate carbohydrate and kinetics Post-meal excursion/late low
Exercise Adjust insulin, food, target Immediate or delayed low; hyperglycemia
Devices Insert, charge, pair, calibrate, troubleshoot Data/delivery interruption
Illness Ketones, hydration, insulin, escalation DKA
Social Disclose, explain, negotiate accommodation Stigma or unsafe concealment
Administration Insurance, prescriptions, school/work forms Interrupted therapy

Contemporary fully closed-loop users describe reduced cognitive workload as well as new questions of trust, control, alarms, and system adaptation (Lakshman 2024, PMID 38426909). Technology changes the work rather than abolishing it.

Free-text responses from 535 people using diabetes technology broaden the burden ledger beyond glucose metrics: waste, travel logistics, administrative effort, device security, and supply continuity were recurring concerns (Everett 2026, PMID 42479430). These costs are easy to miss when trials count sensor wear but not phone compatibility, packaging, replacement calls, prior authorization, or backup therapy.

Treatment trade-offs reported by patients

Choice Valued benefit Experienced cost or uncertainty
Pump/AID More time in range, flexibility, less calculation Body attachment, alarms, trust, infusion failure
CGM sharing Remote reassurance and rescue Surveillance, privacy, alert fatigue
Multiple daily injections Familiarity and independence from hardware Repeated public dosing and more manual calculation
Screening before symptoms Time to prepare and lower DKA risk Prolonged uncertainty and altered identity
Transplantation Freedom from severe hypoglycemia/insulin in responders Immunosuppression, procedures, graft uncertainty
Research participation Access, contribution, hope Visit burden, uncertain benefit, loss of privacy

A mixed-methods systematic review of 19 studies found that adults value glycemic benefit, convenience, flexibility, and reduced injection burden, but place different weights on alarms, device visibility, control, and adverse events (Muñoz-Velandia 2019, PMID 30839227). Preference heterogeneity is therefore a result, not noise to be averaged away.

Diagnosis and family experience

Parents’ mixed-studies review found shock, grief, vigilance, nocturnal fear, relationship strain, and gradual adaptation (Whittemore 2012, PMID 22581804). Presymptomatic screening changes this trajectory by moving uncertainty before symptoms; monitoring guidance therefore embeds psychosocial support (Phillip 2024, PMID 38912694).

Screening cohorts have not shown a single inevitable psychological trajectory. Anxiety can rise around notification and monitoring while preparation and reduced diagnostic crisis may be valued; studies use different respondents, instruments, and follow-up windows (O'Donnell 2023, PMID 37673098). Claims that screening is either harmless or intrinsically harmful exceed the evidence.

Identity synthesis across qualitative studies shows a recurring tension between normality and constant disease work: people may integrate T1D into identity, resist it, or shift between positions by setting and life stage (Ades 2026, PMID 40875389). Advocacy language should allow those positions to coexist.

Stigma and disclosure

Stigma includes blame for food or lifestyle, misidentification with type 2 diabetes stereotypes, unwanted attention during injections, and fear of being treated as unsafe or incapable. Systematic review links stigma with concealment and management burden (Embick 2024, PMID 38361327).

Setting Common friction Useful system response
School Restricted device/food access Individual health plan and trained staff
Work Breaks, privacy, shift variability Explicit accommodation and emergency plan
Sport Pressure to hide or overcorrect Coach/team education and individual plan
Driving Fear, disclosure, legal rules Consistent glucose-safety practice
Social eating Intrusive comments, dosing visibility Preference-sensitive disclosure

The 2024 stigma review included 19 studies and found concealment, disrupted self-management, and emotional harm across quantitative and qualitative designs (Embick 2024, PMID 38361327). An adolescent meta-synthesis adds age-specific contexts such as school surveillance, peer exclusion, and visible devices (Wang 2025, PMID 40515441). Neither synthesis provides a universal prevalence because definitions and sampling differ.

Access as a clinical determinant

Global care availability varies substantially; a survey documents major gaps in pediatric diabetes services and technologies (Pulungan 2023, PMID 37362165). The global model estimates remaining life expectancy after diagnosis at age 10 from 13 years in low-income to 65 years in high-income settings (Gregory 2022, PMID 36113507).

Within high-income systems, racial-ethnic disparities in pump and CGM uptake persist in young adults and safety-net care (Agarwal 2021, PMID 33155826; Fantasia 2021, PMID 33719610). Advocacy for “choice” is incomplete unless insulin, sensors, infusion sets, training, and backup supplies are continuously affordable.

Observed disparities can arise at sequential gates: specialist access, clinician offering, insurer authorization, up-front cost, training, language support, compatible phones, reliable delivery, and replacement after failure. Qualitative work on insulin and device access emphasizes that acquisition and sustained use are separate outcomes (Sklar 2026, PMID 41996632). Reporting only “pump use” hides interruptions and rationing.

Access measure Why it is more informative than a yes/no device variable
Days without basal/bolus insulin available Directly captures life-threatening interruption
Sensor/infusion-set gaps per year Captures continuity rather than prescription
Out-of-pocket cost and administrative hours Quantifies nonclinical workload
Training in preferred language Tests whether nominal access is usable
Backup insulin and meter availability Measures resilience to device failure
Discontinuation and reason Distinguishes preference, harm, and forced loss

Advocacy roles

Role Examples of work Evidence caution
Research funding Grants, trial networks, biobanks Funding priority is not prevalence
Policy Insulin access, device coverage, school rights Jurisdiction-specific
Peer support Camps, groups, helplines Participants may not represent all patients
Education DKA awareness, screening, technology Reach and outcome should be measured
Data/research participation Registries, patient priorities Consent and data governance matter

Verified organization details and access dates are cataloged in organizations.

Advocacy evidence should be triangulated. Organizational campaigns establish that a priority is publicly advanced; they do not establish its prevalence or comparative importance. Registry surveys can quantify respondents but inherit participation bias. Qualitative studies explain mechanisms but do not estimate population frequency. Trials establish effects in eligible participants but commonly undercapture burden and discontinuation.

Patient priorities in trial design

Design decision Patient-centered minimum
Outcome selection Include severe events, workload, sleep, distress, and quality of life where relevant
Comparator Describe the real technology and training received, not “usual care” alone
Eligibility Report exclusions for language, device ownership, HbA1c, and prior adherence
Burden Publish visit, wear, blood-draw, travel, and data-upload requirements
Harms Include skin injury, alarm burden, privacy, weight, and treatment discontinuation
Follow-up Report durability after study support or supplied devices end
Governance State data access, secondary use, withdrawal, and community involvement

A qualitative systematic review identified a broad patient-relevant outcome set across 119 studies, demonstrating that biomedical end points capture only part of what matters (Zafra-Tanaka 2025, PMID 40114395). A bionic-pancreas trial’s lived-experience analyses found benefit alongside device-specific adaptation themes in adults and in parent–youth dyads, supporting paired efficacy and experience reporting (Garza 2025, PMID 39212346; Howard 2024, PMID 38591792).

Patient-reported outcomes

Construct Example measure Limitation
Diabetes distress PAID/T1-DDS family Not interchangeable with depression
Fear of hypoglycemia Hypoglycemia Fear Survey Behavior and worry subscales differ
Quality of life Generic and diabetes-specific instruments Generic measures can miss workload
Treatment satisfaction Device/therapy questionnaires Survivorship bias among continuing users
Family impact Parent/caregiver instruments Child and caregiver priorities may diverge

Meta-analysis suggests AID reduces distress on average in users and caregivers, but discontinuers and unequal access must be reported (Canha 2025, PMID 39726162).

Patient-reported outcomes are susceptible to response shift: expectations and internal standards change after diagnosis or technology adoption. Trials should prespecify the construct and minimally important difference rather than selecting a favorable questionnaire after seeing data. Reports should show missingness and discontinuers, not only complete-case mean change.

Pregnancy illustrates why context-specific experience matters. Closed-loop qualitative work described relief from some glucose work alongside continued vigilance and difficulty trusting automation in a period with narrow targets and rapidly changing insulin needs (Farrington 2018, PMID 30288999). Pregnancy-specific effectiveness trials should therefore not substitute general adult satisfaction data.

Sleep, family, work, and school

Sleep meta-analysis estimated children with T1D slept about 26 minutes less than peers and found poorer adult sleep quality, but methods ranged from questionnaires to objective measurement (Reutrakul 2016, PMID 27692274). A systematic review of nocturnal caregiving documents alarm response and repeated overnight management as a family-level exposure (Howard 2025, PMID 40009726).

Work and school safety depend on accommodation plus privacy. A form or policy is not sufficient if staff cannot recognize hypoglycemia, permit food and devices, or support insulin/ketone management. Conversely, disclosure should be limited to what is needed for safety and chosen participation.

Coverage limits

Published qualitative studies overrepresent people connected to specialty care, research, advocacy, and online communities. English-language public materials underrepresent rural, low-income, insulin-insecure, disabled, older, and non-English-speaking people. Themes in this page are therefore hypotheses about recurring experience, not prevalence estimates.

Three further blind spots should remain visible:

  1. Device studies often exclude people without stable housing, compatible phones, broadband, or dominant-language literacy.
  2. Transplant experience studies capture a highly selected population willing and eligible to accept immunosuppression (Liew 2020, PMID 32815765).
  3. People with recurrent DKA, eating disorders, cognitive disability, or disrupted care are often treated as safety exclusions, removing precisely the experiences most relevant to service redesign.

Open questions

  • Which patient-prioritized outcomes should be mandatory in prevention and AID trials? (Canha 2025, PMID 39726162)
  • How does presymptomatic diagnosis affect identity and family life over 5–10 years? (Phillip 2024, PMID 38912694)
  • Which policy changes measurably reduce insulin interruption and DKA? (Gregory 2022, PMID 36113507)
  • How can patient organizations include people least connected to specialist systems?

References

  1. Whittemore R, et al. Psychological experience of parents of children with T1D. Diabetes Educ. 2012;38:562-579. PMID 22581804
  2. Gregory GA, et al. Global incidence, prevalence, and mortality of T1D in 2021. Lancet Diabetes Endocrinol. 2022;10:741-760. PMID 36113507
  3. Pulungan AB, et al. Availability and access to pediatric diabetes care. Clin Pediatr Endocrinol. 2023;32:137-146. PMID 37362165
  4. Embick R, et al. Impact of stigma on management of T1D. Diabet Med. 2024. PMID 38361327
  5. Lakshman R, et al. Lived Experience of Fully Closed-Loop Insulin Delivery. Diabetes Technol Ther. 2024;26:211-221. PMID 38426909
  6. Phillip M, et al. Monitoring IAb-Positive Pre-Stage 3 T1D. Diabetes Care. 2024;47:1276-1298. PMID 38912694
  7. Canha D, et al. AID and diabetes distress. Diabet Med. 2025. PMID 39726162
  8. Zhang Y, et al. Fear of hypoglycemia: systematic review. J Clin Nurs. 2020. PMID 33091198
  9. Agarwal S, et al. Racial-Ethnic Disparities in Diabetes Technology Use. Diabetes Technol Ther. 2021;23:306-313. PMID 33155826
  10. Fantasia KL, et al. Racial Disparities in Diabetes Technology. J Diabetes Sci Technol. 2021;15:1010-1017. PMID 33719610
  11. Muñoz-Velandia O, et al. Patient values and preferences regarding pumps and artificial pancreas. Diabetes Technol Ther. 2019;21:183-200. PMID 30839227
  12. Reutrakul S, et al. Sleep characteristics in T1D: systematic review and meta-analysis. Sleep Med. 2016. PMID 27692274
  13. O'Donnell HK, et al. Anxiety and Risk Perception in Parents of Children Identified by Population Screening as High Risk for Type 1 Diabetes. Diabetes Care. 2023;46:2155-2161. PMID 37673098
  14. Schipp J, et al. Psychosocial Outcomes Among Users and Nonusers of Open-Source Automated Insulin Delivery Systems. J Med Internet Res. 2023;25:e44002. PMID 38096018
  15. Farrington C, et al. Women's Experiences of Day-and-Night Closed-Loop Insulin Delivery During Type 1 Diabetes Pregnancy. J Diabetes Sci Technol. 2018;12:1125-1131. PMID 30288999
  16. Howard KR, et al. Parent, child, and adolescent lived experience using the insulin-only iLet Bionic Pancreas. J Pediatr Psychol. 2024;49:413-420. PMID 38591792
  17. Garza KP, et al. Adult's Lived Experience Using the Insulin-Only Bionic Pancreas. J Diabetes Sci Technol. 2025;19:11-17. PMID 39212346
  18. Ades R, et al. What does qualitative evidence tell us about how having a diagnosis of type 1 diabetes mellitus impacts an individual's identity? J Health Psychol. 2026;31:983-1000. PMID 40875389
  19. Wang R, et al. Stigma experienced by adolescents with T1D: systematic review and meta-synthesis. Diabet Med. 2025;42:e70088. PMID 40515441
  20. Zafra-Tanaka JH, et al. Patient relevant outcomes for type 1 diabetes management: a qualitative evidence synthesis. Diabet Med. 2025;42:e70016. PMID 40114395
  21. Howard V, et al. Nocturnal caregiving for juveniles with T1D. Psychol Health Med. 2025;30:1701-1722. PMID 40009726
  22. Everett EM, et al. Contemporary Diabetes Technology and the Patient Experience. JAMA Netw Open. 2026;9:e2624260. PMID 42479430
  23. Sklar J, et al. When the system fails: barriers to type 1 diabetes medication access and the emergent role of social media support. Diabet Med. 2026;43:e70313. PMID 41996632
  24. Liew AY, et al. Characterization of pre-transplant psychosocial burden in an integrated national islet transplant program. Islets. 2020;12:21-31. PMID 32815765
  25. Peprah Osei E, et al. Global prevalence and correlates of diabetes distress in T1D. Diabetes Res Clin Pract. 2026;239:113452. PMID 42486409